Y-mAbs Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Y-mAbs Therapeutics Inc YMAB.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of nine analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -31 cents to -19 cents per share.

• Revenue fell 14.4% to $19.53 million from a year ago; analysts expected $18.39 million.

• Y-mAbs Therapeutics Inc's reported EPS for the quarter was a loss of 7 cents​.

• The company reported a quarterly loss of $3.24 million.

• Y-mAbs Therapeutics Inc shares had risen by 88.9% this quarter and gained 8.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 7.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its last closing price of $8.52

This summary was machine generated from LSEG data August 8 at 02:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)